TGNA:FRA
Transgene SA
€0.67
arrow_downward
-0.59%(-0.0040) 1D
Oct 14, 8:03:02 AM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TGNA...
Open
€0.67
High
€0.67
Low
€0.67
Mkt. cap
193.88M
Avg. vol.
0.00
Volume
0.00
52-wk high
€1.48
52-wk low
€0.60
EPS
-€0.17
No. of employees
152
Open
€0.67
High
€0.67
Low
€0.67
Mkt. cap
193.88M
Avg. vol.
0.00
Volume
0.00
52-wk high
€1.48
52-wk low
€0.60
EPS
-€0.17
No. of employees
152
News stories
From web sources and news partners
Seeking Alpha
·
35 minutes ago
S&P 500 sectors face strong historical tailwinds after mid-October close
ChartMill
·
51 minutes ago
These S&P500 stocks are gapping in today's session
TradingView
·
1 hour ago
The Dow Jones Index Opens 0.26% Higher
Yahoo Finance
·
1 hour ago
This ETF Has Crushed the S&P 500 in 2026. Here's Why I Think It Still Has Room to Grow.
Profile
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
About Transgene SA